COMMUNIQUÉS West-GlobeNewswire

Replimune to Present at Upcoming Investor Conferences
30/05/2019
WOBURN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members [...]
Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
30/05/2019
BOSTON, May 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic [...]
Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference
30/05/2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced [...]
Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
30/05/2019
DALLAS and FORT WORTH, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) [...]
Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting
30/05/2019
EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, [...]
Immuron Announces the Closing of Public Offering of ADSs
30/05/2019
MELBOURNE, Australia, May 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the [...]
Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference
30/05/2019
WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced [...]
Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice
30/05/2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today [...]
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
30/05/2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to [...]
CorVel Announces Revenues and Earnings
30/05/2019
IRVINE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter and fiscal year ended March 31, 2019. Revenues for the quarter ended March 31, 2019 were $151 [...]
So-Young Reports First Quarter 2019 Unaudited Financial Results
30/05/2019
BEIJING, May 30, 2019 (GLOBE NEWSWIRE) -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the most popular online destination for discovering, evaluating and reserving medical aesthetic services [...]
Tempus Announces $200 Million in Series F Financing
30/05/2019
CHICAGO, May 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M [...]
Mesoblast Financial Results Webcast for Period Ended March 31, 2019
30/05/2019
MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the period ended March 31, 2019 in a webcast beginning at 6:30pm on Thursday [...]
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
30/05/2019
LONDON, May 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that the Company’s [...]
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
30/05/2019
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of study to be available [...]
Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
30/05/2019
Low dose QMF149 ( indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled corticosteroid ( [...]
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
30/05/2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today [...]
Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease
30/05/2019
MELBOURNE, Australia and NEW YORK, May 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it has filed the first [...]
Helix BioPharma Corp. Closes Private Placement
30/05/2019
RICHMOND HILL, Ontario, May 29, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment [...]

Pages